HCW Biologics settles $2.8M in disputed payables; lien removed, EirGenix obligation cleared

HCW Biologics Inc.

Settlement extinguishes $2.8 million in disputed accounts payable, reported in Q2 ending June 30, 2026.
B&I Contractors dismissed crossclaims with prejudice and filed satisfaction of $1.1M mechanics' lien on company property.
Company paid $1.24M to EirGenix under settlement reducing original $1.7M obligation; final payment on May 26, 2026.
Two $620k payments (March 3 and May 26, 2026) fully settled disputed EirGenix manufacturing costs.
All outstanding amounts related to these disputes are fully resolved with no remaining liabilities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.